載入...
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
Double/triple-hit lymphomas (DHL/THL) account for 5–10% of diffuse large B cell lymphoma (DLBCL) with rearrangement of MYC and BCL2 and/or BCL6 resulting in MYC overexpression. Despite the poor prognosis of DHL, R-CHOP chemotherapy remains the treatment backbone and new targeted therapy is needed. W...
Na minha lista:
| 發表在: | J Hematol Oncol |
|---|---|
| Main Authors: | , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6617630/ https://ncbi.nlm.nih.gov/pubmed/31288832 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0761-2 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|